Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RECOVER trial of eflapegrastim versus pegfilgrastim in chemotherapy-induced neutropenia
2016-003469-24Phase 3Completed
- Sponsor
- Spectrum Pharmaceuticals, Inc.
- Start
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of esketamine in chemotherapy-induced neutropenia (CIN) (2 arms), sponsored by Spectrum Pharmaceuticals, Inc. Primary endpoint: Duration of severe neutropenia in Cycle 1. Started Nov 2016; status: completed.
02
Drugs
esketamine
03
Conditions
chemotherapy-induced neutropenia (CIN)
Beyond the preview
Go deeper on 2016-003469-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003469-24.